
Variable
OR (95% CI)
P
Spirometry (before Bronchodilators)
FEV1%predicted
−1.63 (−2.37 to −0.90)
< 0.001*
Never smoker
−1.28 (−2.44 to −0.12)
0.031*
Ever smoker
−1.85 (−2.80 to −0.91)
< 0.001*
FVC%predicted
−0.89 (−1.55 to −0.24)
0.008*
Never smoker
−1.38 (−2.46 to −0.29)
0.013*
Ever smoker
−0.63 (−1.46 to 0.19)
0.130
FEV1/FVC
−0.70 (−1.10 to −0.30)
< 0.001*
Never smoker
−0.00 (−0.59 to 0.59)
0.995
Ever smoker
−1.11 (−1.65 to −0.58)
< 0.001*
−2
−1
0
1


Variable
Estimate (95% CI)
P for trend
COPD
1.15 (1.06 to 1.25)
< 0.001*
Never smoker
1.18 (1.02 to 1.36)
0.023*
Ever smoker
1.13 (1.02 to 1.26)
0.017*
Respiratory symptom
Cough
1.05 (0.97 to 1.13)
0.250
Never smoker
1.06 (0.92 to 1.21)
0.440
Ever smoker
1.04 (0.94 to 1.14)
0.447
Phlegm production
1.08 (1.00 to 1.16)
0.056
Never smoker
1.08 (0.94 to 1.24
0.259
Ever smoker
1.07 (0.98 to 1.18)
0.128
Dyspnoea
1.08 (1.00 to 1.17)
0.040*
Never smoker
1.07 (0.93 to 1.23)
0.323
Ever smoker
1.10 (0.99 to 1.21)
0.066
0.5
1
1.5
odds ratio per 1 mg/dl increase in uric acid

Figure A1


Variable
OR (95% CI)
P
Spirometry (before Bronchodilators)
FEV1%predicted
−1.63 (−2.37 to −0.90)
< 0.001*
Male
−1.96 (−2.81 to −1.11)
< 0.001*
Female
−1.19 (−2.60 to 0.22)
0.098
FVC%predicted
−0.89 (−1.55 to −0.24)
0.008*
Male
−0.92 (−1.65 to −0.18)
0.015*
Female
−1.44 (−2.84 to −0.04)
0.044*
FEV1/FVC
−0.70 (−1.10 to −0.30)
< 0.001*
Male
−0.97 (−1.45 to −0.49)
< 0.001*
Female
0.06 (−0.66 to 0.77)
0.879
−2
−1
0
1


Variable
Estimate (95% CI)
P for trend
COPD
1.15 (1.06 to 1.25)
< 0.001*
Male
1.15 (1.05 to 1.27)
0.003*
Female
1.15 (0.94 to 1.39)
0.154
Respiratory symptom
Cough
1.05 (0.97 to 1.13)
0.250
Male
1.04 (0.95 to 1.13)
0.350
Female
1.06 (0.87 to 1.27)
0.573
Phlegm production
1.08 (1.00 to 1.16)
0.056
Male
1.07 (0.99 to 1.17)
0.100
Female
1.07 (0.89 to 1.28)
0.471
Dyspnoea
1.08 (1.00 to 1.17)
0.040*
Male
1.07 (0.97 to 1.17)
0.172
Female
1.19 (1.00 to 1.42)
0.045*
0.5
1
1.5

Figure A2


Variable
Estimate (95% CI)
P
Spirometry (after Bronchodilators)
FEV1%predicted
−1.46 (−2.16 to −0.76)
< 0.001*
NonCOPD
−0.36 (−1.13 to 0.40)
0.356
COPD
−1.69 (−2.69 to −0.68)
< 0.001*
FVC%predicted
−0.62 (−1.25 to −0.00)
0.050
NonCOPD
−0.37 (−1.17 to 0.44)
0.376
COPD
−1.12 (−2.07 to −0.18)
0.019*
FEV1/FVC
−0.79 (−1.19 to −0.39)
< 0.001*
NonCOPD
−0.02 (−0.28 to 0.25)
0.905
COPD
−0.68 (−1.16 to −0.20)
0.005*
−2
−1
0
1

Figure A3

Figure A1: Association of SUA with study outcomes stratified by smoking status. Shown are odds ratio or estimate for each outcome for per 1 mg/dl increase in serum uric acid, adjusted for age, sex, BMI, and cumulative tobacco consumption.

Abbreviation: Ever-smokers, former and current smokers combined. COPD, chronic obstructive pulmonary disease; OR, odds risk; 95% CI, 95% confidence interval.

Bold values means that all participants were in the analysis.

* *p* value less than 0.05.

Figure A2: Association of SUA with study outcomes stratified by gender. Shown are odds ratio or estimate effect for each outcome for per 1 mg/dl increase in serum uric acid, adjusted for age, BMI, smoking status, and cumulative tobacco consumption.

Abbreviation: COPD, chronic obstructive pulmonary disease; FEV1% predicted, percent predicted forced expiratory volume in 1 s; FVC% predicted, percent predicted forced vital capacity; OR, odds risk; 95% CI, 95% confidence interval.

Bold values means that all participants were in the analysis.

* *p* value less than 0.05.

Figure A3： Association of SUA with lung function after bronchodilators. Shown are estimates for each outcome for per 1 mg/dl increase in serum uric acid, adjusted for age, BMI, smoking status, and cumulative tobacco consumption.

Abbreviation: COPD,chronic obstructive pulmonary disease; Non-COPD, without chronic obstructive pulmonary disease; FEV1% predicted, percent predicted forced expiratory volume in 1 s; FVC% predicted, percent predicted forced vital capacity; OR, odds risk; 95% CI, 95% confidence interval.

Bold values means that all participants were in the analysis.

* *p* value less than 0.05.